IL1B and chronic myelogenous leukemia, BCR-ABL1 positive: Apart from anakinra, which is used in managing CAR T adverse events, canakinumab, the IL-1β neutralizing antibody, is being evaluated for the therapeutic effects in MDS and CML [8,9].